NOCDURNA Drug Patent Profile
✉ Email this page to a colleague
When do Nocdurna patents expire, and what generic alternatives are available?
Nocdurna is a drug marketed by Ferring Pharms Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has one hundred and thirty-six patent family members in thirty-four countries.
The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nocdurna
A generic version of NOCDURNA was approved as desmopressin acetate by HONG KONG on October 15th, 1997.
Summary for NOCDURNA
| International Patents: | 136 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Clinical Trials: | 1 |
| Patent Applications: | 498 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NOCDURNA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NOCDURNA |
| What excipients (inactive ingredients) are in NOCDURNA? | NOCDURNA excipients list |
| DailyMed Link: | NOCDURNA at DailyMed |
Recent Clinical Trials for NOCDURNA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ferring Pharmaceuticals | Phase 2 |
Pharmacology for NOCDURNA
| Drug Class | Factor VIII Activator Vasopressin Analog |
| Physiological Effect | Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration |
Anatomical Therapeutic Chemical (ATC) Classes for NOCDURNA
US Patents and Regulatory Information for NOCDURNA
NOCDURNA is protected by eleven US patents.
Patents protecting NOCDURNA
Methods comprising desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
Pharmaceutical formulations of desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods comprising desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
Orodispersible dosage forms of desmopressin acetate
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Pharmaceutical formulations
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Methods of treatment using orodispersible desmopressin pharmaceutical formulations
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Methods using desmopressin acetate in orodispersible form
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Pharmaceutical formulations of desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Pharmaceutical formulations of desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Methods comprising desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
Methods comprising desmopressin
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-001 | Jun 21, 2018 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ferring Pharms Inc | NOCDURNA | desmopressin acetate | TABLET;SUBLINGUAL | 022517-002 | Jun 21, 2018 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NOCDURNA
International Patents for NOCDURNA
See the table below for patents covering NOCDURNA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2006502972 | ⤷ Try a Trial | |
| Lithuania | PA2017001 | ⤷ Try a Trial | |
| Austria | 333886 | ⤷ Try a Trial | |
| Japan | 2018035198 | 夜間頻尿によって妨げられない睡眠の初期期間を増加させるための口腔内崩壊デスモプレシン (ORODISPERSIBLE DESMOPRESSIN FOR INCREASING INITIAL PERIOD OF SLEEP UNDISTURBED BY NOCTURIA) | ⤷ Try a Trial |
| Portugal | 3225249 | ⤷ Try a Trial | |
| Norway | 2019021 | ⤷ Try a Trial | |
| Denmark | 1501534 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for NOCDURNA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3225249 | 300983 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513 |
| 2712622 | PA2017001,C2712622 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESINAS ARBA JO ACETATO DRUSKA; REGISTRATION NO/DATE: BE497271, 2016-05-04; LT1-16/3940/001-LT/1 6/3940/008 |
| 2712622 | LUC00015 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101 |
| 2712622 | C02712622/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018 |
| 3225249 | CA 2019 00023 | Denmark | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504 |
| 3225249 | 2019C/520 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513 |
| 2712622 | 122017000006 | Germany | ⤷ Try a Trial | PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
